Questions and responses 45th Parliament, 1st session May 26, 2025, to present

With regard to Veterans Affairs Canada: (a) prior to the reduction, how many veterans were receiving cannabis at a price point higher than $6.00 per gram as of April 1, 2026, when the reimbursement rate for cannabis for medical purposes was cut from $8.50 per gram to $6.00 per gram; (b) what was the reimbursement rate for cannabinoid products, such as edibles, oils or creams, which contain delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD) (i) as of April 1, 2026, (ii) prior to April 1, 2026; (c) what is the total number of veterans who receive reimbursements for (i) cannabis, (ii) cannabinoid products, (iii) opioid products; and (d) what was the total amount paid out in the last year for which figures are available, in reimbursements for (i) cannabis, (ii) cannabinoid products, (iii) opioids?

With regard to the government and cannabis: (a) how much revenue has the government received from excise duties and other taxes on cannabis, since January 2019, in total, and broken down by year; (b) what is the breakdown of (a) by province or territory, and type of tax or duty; and (c) how much has the government spent on cannabis warnings and the prevention of cannabis usage each year, in total and broken down by educational or advertising campaign?

With regard to personal and designated production of cannabis for medical purposes under the Cannabis Act and associated regulations: (a) how many personal or designated production registrations are currently authorized by Health Canada, broken down by province or territory; (b) of the registrations in (a), how many authorize more than (i) 10, (ii) 50, (iii) 100, plants; (c) what monitoring, inspection or compliance verification activities does Health Canada conduct after a registration for personal or designated production has been granted; (d) how often are inspections or follow-up reviews conducted, and what triggers such inspections or reviews; (e) how does Health Canada verify that registered individuals are complying with authorized plant limits; (f) what measures are in place to prevent diversion of cannabis grown under personal or designated production registrations to the illegal market; (g) what requirements, if any, exist to ensure that cannabis grown in residential settings is produced in a manner that does not pose risks related to mold, electrical safety, fire hazards or any other public health and safety concern; (h) what role, if any, do the Royal Canadian Mounted Police or local law enforcement agencies play in monitoring compliance with personal or designated production registrations; (i) is there a formal process by which neighbours, municipalities or members of the public can submit complaints to Health Canada, the Royal Canadian Mounted Police or local law enforcement regarding suspected non‑compliance with a personal or designated production registration, and, if so, what is the process; (j) if such a complaint process does exist, how many complaints have been received in each of the past five years, and how many resulted in inspections or enforcement action; (k) if no such complaint-triggered inspection process exists, why not; and (l) what steps, if any, is the government planning to strengthen oversight, accountability and community protections related to personal and designated cannabis production registrations, particularly where large-scale production is authorized in residential areas?

With regard to Veterans Affairs Canada in the last fiscal year: (a) how much was spent on service dogs for veterans; (b) how many veterans received service dogs; (c) how much was spent on cannabis for veterans; (d) how many veterans received cannabis; and (e) how much was spent on drugs and substances, other than cannabis, which are listed under the Controlled Drugs and Substances Act, in total and broken down by amount spent?